Ocuphire Pharma
summary of ophthalmic solution trial results post dose bree nea mild | Ocuphire Pharma
Company
Deck Type
Deck date
November 2023
Slide
35 of 42
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Investor Presentation
August 2023
summary of trial results | Ocuphire Pharma
Investor Presentation
May 2023
summary of trial results | Ocuphire Pharma
Related slides by other companies
Oculis
Results
August 2023
in phase optimize trial meets both primary | Oculis
Aeglea BioTherapeutics
Investor Presentation
August 2020
pivotal phase peace trial design | Aeglea BioTherapeutics
Aeglea BioTherapeutics
Results
December 2021
primary met marked and sustained reduction in plasma arginine | Aeglea BioTherapeutics
argenx SE
Results
December 2022
efficacy primary and all platelet related secondary were met | argenx SE
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights